Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

Related Keywords

United States ,Eiryw Roberts ,Neurocrine Biosciences ,Neurocrine Biosciences Inc ,Linkedin ,Takeda Pharmaceutical Company Ltd ,Facebook ,Twitter ,Nasdaq ,Chief Medical Officer ,Depression Rating ,Takeda Pharmaceutical Company ,